Dynavax Technologies Corp. investors rejoiced Thursday as positive top-line results from a phase III trial comparing the safety and immunogenicity of its investigational hepatitis B vaccine, Heplisav-B, to Glaxosmithkline plc's Engerix-B emboldened the Berkeley, Calif.-based company to resubmit its biologics license application (BLA) for the therapy by the end of March.